Cardiff Oncology Inc (NASDAQ:CRDF) shares, rose in value on Wednesday, April 16, with the stock price down by -4.42% to the previous day’s close as strong demand from buyers drove the stock to $2.81.
Actively observing the price movement in the last trading, the stock closed the session at $2.94, falling within a range of $2.79 and $3.0399. The value of beta (5-year monthly) was 1.734. Referring to stock’s 52-week performance, its high was $5.64, and the low was $2.01. On the whole, CRDF has fluctuated by -25.86% over the past month.
With the market capitalization of Cardiff Oncology Inc currently standing at about $186.93 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 89.29k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRDF’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of CRDF currently trading nearly -8.53% and -25.06% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.65, while the 7-day volatility ratio is showing 10.31% which for the 30-day chart, stands at 7.88%. Furthermore, Cardiff Oncology Inc (CRDF)’s beta value is 1.79, and its average true range (ATR) is 0.28.
A comparison of Cardiff Oncology Inc (CRDF) with its peers suggests the former has fared considerably weaker in the market. CRDF showed an intraday change of -4.42% in last session, and over the past year, it shrunk by -46.78%%.
Data on historical trading for Cardiff Oncology Inc (NASDAQ:CRDF) indicates that the trading volumes over the past 10 days have averaged 1.82 and over the past 3 months, they’ve averaged 1.20 million. According to company’s latest data on outstanding shares, there are 66.52 million shares outstanding.
Nearly 10.13% of Cardiff Oncology Inc’s shares belong to company insiders and institutional investors own 34.57% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.81 million shares as on 2025-03-31, resulting in a short ratio of 12.47. According to the data, the short interest in Cardiff Oncology Inc (CRDF) stood at 2270.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 11.38 million. The stock has fallen by -35.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDF stock heading into the next quarter.
